Alternating hemiplegia of childhood (AHC) is a rare neurodevelopmental disorder in which infants develop recurring episodes of temporary paralysis that can shift from one side of the body to the other, typically beginning before 18 months of age.1PubMed Central. Navigating the Complexity of Alternating Hemiplegia in Childhood: A Comprehensive Review Most cases trace to spontaneous mutations in a single gene, and the condition involves far more than just paralysis: seizures, movement abnormalities, autonomic dysfunction, and intellectual disability are all part of the picture. Because it is so rare and so variable in how it looks, AHC is frequently misdiagnosed for years before families get an answer.
What Happens During an Episode
The hallmark of AHC is episodes of hemiplegia, meaning weakness or paralysis affecting one side of the body, that can last anywhere from minutes to days. These episodes alternate sides, which is where the condition gets its name. Sometimes both sides are affected simultaneously, producing quadriplegia, which tends to be more dangerous. The paralysis is temporary; between episodes, muscle function returns, though not always completely over time.
But hemiplegia is only one piece of the clinical picture. Children with AHC also experience a range of other paroxysmal events, including dystonia (sustained abnormal postures and muscle contractions), tonic spells, and abnormal eye movements. Nystagmus affecting just one eye is a particularly distinctive early sign and can appear either on its own or alongside tonic or dystonic episodes.2PubMed Central. Alternating hemiplegia of childhood: a distinct clinical entity and ATP1A3-related disorders: A narrative review Autonomic dysfunction, including changes in skin color, breathing irregularities, and heart rate fluctuations, can also occur during or between attacks.3Pediatric Neurology. Diagnosis and treatment of alternating hemiplegia of childhood
One of the most striking features of AHC is its relationship with sleep. Episodes resolve when the child falls asleep. This is so consistent that it serves as both a diagnostic clue and a frontline management strategy. However, symptoms can return shortly after waking, sometimes within minutes.
The ATP1A3 Gene and Why It Matters
The genetic basis of AHC was identified in 2012, when independent research groups found that the vast majority of cases are caused by de novo mutations in the ATP1A3 gene. “De novo” means the mutation is new in the child and was not inherited from either parent. In one landmark study, all 24 patients with AHC carried disease-associated mutations in ATP1A3, including missense mutations and one splice-site mutation.4The Lancet Neurology. De-novo mutations in ATP1A3 cause alternating hemiplegia of childhood Parallel work in Japanese patients confirmed the same gene as the culprit in sporadic cases.5PLoS ONE. Identification of ATP1A3 Mutations by Exome Sequencing as the Cause of Alternating Hemiplegia of Childhood in Japanese Patients
ATP1A3 encodes one subunit of the sodium-potassium pump, a protein found throughout the brain that is essential for maintaining the electrical balance of nerve cells. When this pump doesn’t work properly, neurons become unstable. Research using neurons derived from AHC patients has shown that the pump current is significantly reduced compared with healthy neurons, and that this leads to a more depolarized (electrically excitable) resting state.6PubMed. Direct evidence of impaired neuronal Na/K-ATPase pump function in alternating hemiplegia of childhood In practical terms, the neurons are sitting closer to their firing threshold than they should be, making them more susceptible to the kind of runaway electrical activity that produces symptoms.
Not All Mutations Are Equal
Three specific mutations in ATP1A3 account for a large share of AHC cases: D801N, E815K, and G947R. These are not interchangeable. The specific mutation a child carries has a real effect on how severe their disease is likely to be.
The E815K mutation is consistently associated with the most severe form of AHC. In a study of 187 patients from the US AHC Foundation registry, children with E815K had symptom onset about 2.7 months earlier than those with D801N or other mutations, achieved unsupported sitting later, and were almost three times more likely to develop status epilepticus (prolonged, uncontrolled seizures) over the course of the disease.7PLOS ONE. Alternating Hemiplegia of Childhood: Retrospective Genetic Study and Genotype-Phenotype Correlations in 187 Subjects from the US AHCF Registry A separate analysis found that E815K carriers also had greater motor and intellectual disability than those with D801N or G947R mutations, and a higher proportion developed epilepsy.8PubMed Central. Genotype-phenotype correlation in patients with alternating hemiplegia of childhood
The D801N mutation tends to fall in the middle of the severity spectrum. The G947R mutation is generally associated with a later age of onset and milder developmental impacts, though “milder” here is relative. All three mutations still produce a serious neurological condition. There are also rarer, less well-characterized mutations in ATP1A3 that can cause AHC, and a small percentage of clinically diagnosed patients have no identifiable ATP1A3 mutation at all.
Why Diagnosis Takes So Long
AHC is estimated to affect roughly one in a million children, though this figure is likely an undercount because the condition is underrecognized. Variability in how it presents, limited familiarity among clinicians, and the absence of a definitive laboratory or imaging test that confirms AHC before genetic testing all contribute to diagnostic delays that can stretch over a decade in some cases.9PubMed Central. More Than a Decade of Misdiagnosis of Alternating Hemiplegia of Childhood with Catastrophic Outcome
Because hemiplegic episodes can look like seizures or strokes, children with AHC are frequently misdiagnosed with epilepsy, hemiplegic migraine, or cerebral palsy. Brain imaging is typically normal, and standard EEG may not show the classic epileptiform patterns that would point to a seizure disorder. That mismatch between dramatic clinical episodes and unremarkable test results is itself a diagnostic clue, but only if the clinician knows to look for it.
There are a few clinical features that, taken together, strongly suggest AHC: episodes of hemiplegia that alternate sides, quadriplegic episodes, paroxysmal nystagmus (especially monocular), dystonic spells, and the consistent resolution of symptoms with sleep.10PubMed Central. Alternating Hemiplegia of Childhood: Understanding the Genotype-Phenotype Relationship of ATP1A3 Variations Genetic testing for ATP1A3 mutations can confirm the diagnosis, and the availability of this testing has meaningfully shortened the diagnostic journey for many families since 2012. Still, the test has to be ordered in the first place, which requires the clinician to suspect AHC.
Epilepsy and AHC
Roughly half of people with AHC also develop true epilepsy, meaning seizures that are distinct from and in addition to the hemiplegic episodes themselves.11PubMed. The treatment and management of alternating hemiplegia of childhood This distinction matters because hemiplegic episodes are not seizures, even though they can look similar from the outside. The underlying electrical activity in the brain during a hemiplegic episode is different from what happens during an epileptic seizure, and the treatments are not the same.
The epileptic seizures that develop in AHC patients tend to appear in childhood and can take various forms: generalized tonic-clonic, myoclonic, tonic, or focal seizures, sometimes accompanied by cyanosis (blue discoloration from low oxygen) or prolonged respiratory arrest.12PubMed. Evolution of hemiplegic attacks and epileptic seizures in alternating hemiplegia of childhood A subset of patients can develop refractory or super-refractory status epilepticus, meaning prolonged seizures that do not respond to standard treatments.13PubMed Central. Practical management of repeated life-threatening status epilepticus in Alternating Hemiplegia of Childhood: Case report and literature review These episodes are medical emergencies and represent one of the most dangerous complications of AHC.
Because hemiplegic episodes and epileptic seizures often coexist and can be difficult to distinguish clinically, getting an accurate characterization of what type of event a child is having is critical for guiding treatment. Anti-seizure medications may help with the epilepsy component but do not prevent hemiplegic episodes.
Triggers and Episode Management
Many AHC episodes have identifiable triggers. Common ones include emotional stress, physical exertion, temperature extremes (particularly exposure to cold or hot water), bright lights, and illness. Identifying and avoiding a child’s specific triggers is one of the main strategies families use to reduce episode frequency, though complete avoidance is rarely possible.
When an episode does begin, the most effective acute intervention is sleep. Because symptoms reliably resolve during sleep, encouraging a child to fall asleep as quickly as possible can shorten an attack. Some families use sleep-inducing medications when an episode starts, though this approach has practical limits and doesn’t address the underlying biology. Avoiding trigger situations and rapidly encouraging sleep when attacks begin have been described as cornerstones of day-to-day management alongside drug therapy.14PubMed. The treatment and management of alternating hemiplegia of childhood
Flunarizine and the Limits of Current Treatment
Flunarizine, a calcium channel blocker, has been the most widely used medication for AHC for decades, though the evidence behind it is limited and the results are mixed. In one study of 10 patients treated for up to five years, flunarizine reduced the duration of hemiplegic attacks, but episodes ceased completely in only one patient.15PubMed. Alternating hemiplegia of childhood: a study of 10 patients and results of flunarizine treatment A larger Japanese study of 28 patients found that flunarizine reduced the severity, duration, or frequency of attacks in about two-thirds of those treated, and some patients also showed benefits in motor and intellectual development over the long term.16PubMed. Long-term effect of flunarizine on patients with alternating hemiplegia of childhood in Japan
That said, flunarizine is not a cure and does not work equally well for everyone. Its effectiveness may be influenced by the specific ATP1A3 mutation involved. In one case report of a patient with the severe E815K mutation, flunarizine had limited overall therapeutic effect, though it did help with one specific symptom, bulbar palsy (difficulty swallowing and speaking).17PubMed Central. Effect of Flunarizine on Alternating Hemiplegia of Childhood in a Patient with the p.E815K Mutation in ATP1A3: A Case Report Flunarizine is not available in all countries, which adds a practical barrier for some families.
Beyond flunarizine, there is no drug that has been shown to consistently prevent hemiplegic episodes. Anti-seizure medications are used for patients who have epilepsy as part of their AHC, and a variety of other drugs have been tried on a case-by-case basis, including benzodiazepines and other sedatives to abort acute episodes. None has emerged as a reliable standard treatment.
Cardiac Risks That Families Should Know About
One of the less recognized but potentially most dangerous aspects of AHC is its effect on the heart. Autonomic dysfunction has long been known to accompany AHC episodes, but research has identified a more specific cardiac concern. Patients with AHC, particularly those carrying the D801N mutation, have been found to have significantly shorter QTc intervals on electrocardiogram and an increased likelihood of bradycardia associated with life-threatening arrhythmias.18Journal of the American Heart Association. ATP1A3‐Encoded Sodium‐Potassium ATPase Subunit Alpha 3 D801N Variant Is Associated With Shortened QT Interval and Predisposition to Ventricular Fibrillation Preceded by Bradycardia This is significant because ATP1A3 mutations may represent an independent cause of sudden unexplained death, and patients with AHC should be evaluated for cardiac risk.
A separate study noted that premature mortality occurs in the AHC population and is not fully explained by neurological events alone, raising the possibility that preventable cardiorespiratory arrest from underlying cardiac dysrhythmia could be a contributing factor.19Brain. Faulty cardiac repolarization reserve in alternating hemiplegia of childhood broadens the phenotype The mortality rate in AHC has been estimated at roughly 1.1 deaths per 100 patient-years, with sudden unexpected death in epilepsy occurring at approximately 6.5 per 1,000 patient-years.20PubMed Central. Natural History of Alternating Hemiplegia of Childhood: Vulnerabilities in Early Childhood and Predictive Factors for Long-Term Outcomes These numbers underscore the importance of cardiac screening and ongoing monitoring.
What Happens in Adulthood
Despite its name, alternating hemiplegia of childhood does not simply end when a person grows up. Hemiplegic episodes can continue into adulthood, and the cognitive and motor difficulties that develop during childhood tend to persist and, in some cases, worsen. Most adults with AHC have some degree of intellectual disability and motor impairment, though the severity varies widely depending on the mutation and the individual.
Perhaps the most sobering finding from long-term follow-up studies is that AHC is not a stable condition. Some patients experience abrupt, catastrophic neurological deterioration in adulthood. In one study, three out of seven patients deteriorated suddenly between the ages of 19 and 34, triggered by a febrile illness that led to a prolonged quadriplegic episode, status epilepticus, or both. These adults went from walking independently to being wheelchair-bound, and from being mildly dysarthric to near-complete loss of language function.21PubMed Central. Non‐Stationary Outcome of Alternating Hemiplegia of Childhood into Adulthood These events highlight the vulnerability of the AHC brain to acute stressors and the importance of aggressive management of febrile illnesses and prolonged episodes.
The Impact on Families
Living with AHC affects the entire family, not just the child. The unpredictability of episodes, the need for constant vigilance around triggers, the frequent medical appointments, and the progressive cognitive and motor challenges all impose a substantial burden on caregivers. Research has confirmed that AHC has a significant impact on families, affecting emotional well-being, social participation, and financial stability.22PubMed. Caregiver’s burden and psychosocial issues in alternating hemiplegia of childhood
For families navigating this condition, connecting with the AHC Foundation and similar advocacy groups can be a lifeline. These organizations provide support networks, help families access genetic testing and specialist care, and fund research. Because AHC is so rare, even experienced pediatric neurologists may have seen only a handful of cases. Patient registries maintained by these organizations have been essential for building the kind of large-scale data that individual clinics cannot generate alone, including the genotype-phenotype work that now helps clinicians give families more specific prognostic information based on their child’s mutation.
Emerging Research and Future Therapies
The past decade has seen a meaningful acceleration in AHC research, driven in part by the identification of ATP1A3 as the causative gene. Knowing the genetic target has opened the door to therapy strategies that were not possible when AHC was a clinical diagnosis without a known molecular cause. Emerging therapeutic approaches now under exploration include gene therapy, antisense oligonucleotides (which aim to correct or silence the faulty gene’s message), and small-molecule interventions designed to compensate for the sodium-potassium pump dysfunction.23PubMed Central. Alternating Hemiplegia of Childhood and ATP1A3-Related Diseases: Insights From a Decade of Discovery and Collaboration
Animal models have been critical to this effort. Several genetically engineered mouse lines that replicate key features of AHC have been developed and are being used to study both the underlying brain dysfunction and potential treatments. Their short generation time makes them suitable for relatively rapid screening of candidate drugs and genetic modifiers.24PubMed Central. Genetically altered animal models for ATP1A3-related disorders Zebrafish and fruit fly models also exist and offer complementary advantages for high-throughput screening.
None of these newer approaches is yet available as a clinical treatment. The rarity of AHC makes clinical trials challenging to design and recruit for, and the variability of the condition means that demonstrating a treatment effect requires careful outcome measures. But the trajectory is genuinely hopeful compared with even a decade ago, when families had essentially no disease-specific therapy and no clear understanding of what was going wrong at the molecular level. The integration of patient registries, basic science, and advocacy efforts is building the infrastructure that targeted treatments for ultra-rare diseases require.
Cortical Spreading Depression and the Brain During Episodes
There is ongoing scientific debate about exactly what is happening in the brain during a hemiplegic episode. One leading hypothesis involves cortical spreading depression (CSD), a wave of intense neuronal and glial depolarization that slowly sweeps across the brain’s surface, temporarily silencing electrical activity in its wake. CSD is well established as the mechanism behind the aura phase of migraine, and it may also explain the transient paralysis in AHC. The initiation of CSD involves both calcium channels and a specific type of glutamate receptor, requiring a threshold level of activation that develops over several seconds after the initial depolarizing event.25PubMed Central. Mechanisms of initiation of cortical spreading depression
The connection makes intuitive sense: if ATP1A3 mutations leave neurons in a more excitable state due to impaired pump function, the threshold for triggering CSD could be lower, meaning that relatively minor provocations, like a bath that is slightly too warm or an emotional outburst, could set off a wave. This would explain both the transient nature of hemiplegic episodes and their resolution with sleep, since sleep alters neuronal excitability and metabolic recovery. The hypothesis remains unproven in AHC patients, however, because directly measuring CSD in a living human brain is extremely difficult. Much of the supporting evidence comes from animal models and inferences drawn from the clinical overlap between AHC and familial hemiplegic migraine, another channelopathy that involves different ion channel genes but produces similar episodic paralysis.